A 12 Week Open Label, Parallel Group, Comparative, Multicentric Phase III Study to Assess Efficacy and Safety of Metered Dose Buccal Insulin Spray versus Rapid Insulin s.c. on subjects with type II Diabetes who are inadequately controlled i.e. HbA1C 6.5 to 8.5 while on Oral Anti- Diabetic Agents - BUCLAR

开始日期2010-08-17

申办/合作机构

Shreya Life Sciences Pvt Ltd.

[+1]

100 项与 Shreya Life Sciences Pvt Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Shreya Life Sciences Pvt Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Shreya Life Sciences Pvt Ltd. 相关的文献（医药）

2023-03-28·Indian Journal of Pharmacy and Pharmacology

A prospective, post-marketing surveillance (PMS) study to monitor the safety of fixed dose combination of Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg [Recofast Tablets] for the symptomatic relief in patients with upper respiratory tract infections

作者: Patil, Preksha Pramod ; Kadoo, Sachin Madhukar

Upper Respiratory Tract Infection (URTI) is the most frequent illness in humans. The vast majority of acute upper respiratory tract infections are caused by viruses. These cause a variety of patient diseases including acute bronchitis, common cold, influenza, and respiratory distress syndromes.The study was conducted in patients with upper respiratory tract infections to see if the medication provides symptomatic relief in these conditions. Other conditions like allergic rhinitis and influenza were also included in the study for symptomatic relief.This is an open label, multicentric, active Post Marketing Surveillance (PMS) study with an objective to assess safety of fixed dose combination regarding Recofast tablets (Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg) which was evaluated in 150 participants from different geographical regions. And then results were documented. A total of 19 (13%) patients recorded minor adverse event from these regions. Out of 150 patients 95 were male & 55 were female. All the patients were in the range of 18-80 years.No significant adverse events were observed during the course of the study, only 13% patients recorded minor adverse events from all regions. Thus this formulation is completely safe and effective in the management of Upper Respiratory Tract Infections and allergies.

2012-12-13·ISRN Pharmaceutics

Itraconazole Niosomes Drug Delivery System and Its Antimycotic Activity against Candida albicans

Article

作者: Wagh, Vijay D. ; Deshmukh, Onkar J.

Niosomes have potential applications in topical drug delivery system. The objective of the study was to formulate and evaluate the niosome of Itraconazole. Surfactant : cholesterol ratio and quantity of ethanol used were studied by applying factorial design. Formulated niosomes were evaluated for vesicle size, entrapment efficiency, drug release, skin permeation, and antimycotic activity. Vesicle size, entrapment efficiency, and drug release were markedly dependent on surfactant : cholesterol ratio and quantity of ethanol used. Permeation of the drug through the skin was affected by cholesterol content in formulation. Itraconazole niosome were having larger zone of inhibition than marketed formulation when activity was checked against C. albicans. Niosomes may be a promising carrier for topical delivery of Itraconazole especially due to their simple production.

International Journal of Advanced Research in Pharmaceutical & Bio Sciences

Fast dissolving tablets of Pioglitazone hydrochloride by use of various superdisintegrants

作者: Mote, Prakash B. ; Shailendra Singh, K. ; Rawat, Pavan K. ; Salunke, Amarjit A. ; Zadbuke, Nityanand S. ; Rajendra, Vivek B.

The present investigations focus on formulation and evaluation of fast dissolving tablets (FDT) of Pioglitazone hydrochloride.To improve patient compliance, mouth dissolving tablets have emerged as an alternative to conventional dosage forms.Pioglitazone hydrochloride and Sulfonylurea are given in combination for treatment of type II Diabetes Mellitus for long term therapy.During this therapy, it is observed that there is uncontrolled increase of blood glucose level, and the drug undergoes hepatic metabolismTherefore, fast dissolving tablets of Pioglitazone hydrochloride were prepared to overcome this unusual problem and to make use of the inherent advantages of the novel drug delivery system.The tablets were prepared by using direct compression method using superdisintegrants.Tablets containing Pioglitazone, croscarmellose, crospovidone, Indion 414.The tablets were evaluated for weight variation, hardness, %friability, wetting time, and disintegration time.

100 项与 Shreya Life Sciences Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Shreya Life Sciences Pvt Ltd. 相关的转化医学

登录后查看更多信息